Biotech companies are always searching for new ways to fund the costly and uncertain process of drug development and product launch. Over the past several years, synthetic royalty and drug development financings have become an additional option for fundraising, as traditional equity markets have remained challenging. Covington & Burling’s third
Continue Reading Synthetic Royalty and Drug Development Financings – A Funding Structure Growing in Europe
Amy Toro
Amy Toro advises both pharmaceutical and biotechnology companies regarding biologics, pharmaceuticals and devices, including in the digital health space. Amy works on all types of life sciences transactions, including major collaborations, licensing arrangements, clinical trial agreements, supply and distribution agreements, product development funding deals, and joint ventures and a variety of commercial agreements. She also works with her mergers and acquisition colleagues on product divestitures and asset transfers.
She received her J.D. from the Boalt Hall School of Law, University of California, Berkeley in 1994, and a Ph.D. in Jurisprudence and Social Policy in 2000.
Amy has clerked for the Hon. Stephen F. Williams of the U.S. Court of Appeals for the District of Columbia Circuit from 1996 to 1997. She has also served as a visiting professor of law at Northwestern University School of Law and at the University of California, Davis.
She is admitted to the California Bar.